Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7547399 | 0.97 | CYP1A2 (0.56) | CYP1A2CYP2A6TAAR1ALOX15ALDH1A1 | |
| SCHEMBL7376337 | 0.87 | CYP1A2 (0.52) | CYP1A2CYP2A6TAAR1ALOX15ALDH1A1 | |
| SCHEMBL2680220 | 0.85 | CYP1A2 (0.50) | CYP1A2CYP2A6TAAR1ALOX15ALDH1A1 | |
| SCHEMBL7548931 | 0.85 | CYP1A2 (0.50) | CYP1A2CYP2A6TAAR1ALOX15ALDH1A1 | |
| SCHEMBL17403329 | 0.85 | IGF1R (0.53) | CYP1A2CYP2A6TAAR1ALOX15ALDH1A1 | |
| SCHEMBL11288839 | 0.84 | CYP1A2 (0.68) | CYP1A2CYP2A6TAAR1ALOX15ALDH1A1 | |
| SCHEMBL143961 | 0.84 | CYP1A2 (0.68) | CYP1A2CYP2A6TAAR1ALOX15ALDH1A1 | |
| SCHEMBL10685072 | 0.84 | ALDH1A1 (0.69) | CYP1A2CYP2A6TAAR1ALOX15ALDH1A1 | |
| SCHEMBL11395796 | 0.83 | IGF1R (0.52) | CYP1A2CYP2A6TAAR1ALOX15ALDH1A1 | |
| SCHEMBL16744188 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP2A6TAAR1ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024100452-A2 | HETEROCYCLIC COMPOUNDS AS STING AGONISTS | LEGOCHEM BIOSCIENCES, INC. (KR) | 2024-05-16 | — | — | WO | disclosed |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-09 | — | — | US | disclosed |
| EP-2655307-B1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | GIVAUDAN SA (CH) | 2018-08-01 | — | — | EP | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| EP-2807143-B1 | PROCESS FOR PREPARATION OF FINGOLIMOD | GLENMARK GENERICS LTD (IN) | 2017-08-30 | — | — | EP | disclosed |
| US-9649373-B2 | Neoseptins: small molecule adjuvants | THE SCRIPPS INSTITUTE (US) | 2017-05-16 | — | — | US | disclosed |
| US-9637462-B2 | Process for the preparation of N-iodoamides | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-05-02 | — | — | US | disclosed |
| US-20160272598-A1 | PROCESS FOR THE PREPARATION OF N-IODOAMIDES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2016-09-22 | — | — | US | disclosed |
| US-20160000907-A1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| US-9193935-B2 | Compounds capable of releasing fragrant compounds | GIVAUDAN S.A. (CH) | 2015-11-24 | — | — | US | disclosed |
| WO-2012085287-A1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | GIVAUDAN SA (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20110178199-A1 | METHOD FOR PRODUCING ORGANIC COMPOUND AND ORGANIC COMPOUND OBTAINED BY THE METHOD | M. TECHNIQUE CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010078421-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F] ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272598-A1 | PROCESS FOR THE PREPARATION OF N-IODOAMIDES | INMT, NPM1, B2M | CYP1A2 498/4885CYP2A6 1366/4885TAAR1 1083/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | CYP1A2 4762/4885CYP2A6 4354/4885TAAR1 3037/4885 |
| US-20160000907-A1 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS | TLR2, TLR4, TLR1 | CYP1A2 3337/4885CYP2A6 4280/4885TAAR1 1428/4885 |
| US-20110178199-A1 | METHOD FOR PRODUCING ORGANIC COMPOUND AND ORGANIC COMPOUND OBTAINED BY THE METHOD | OR10J3, PORCN, ABCG2 | CYP1A2 527/4885CYP2A6 428/4885TAAR1 1430/4885 |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | NISCH, COASY, KLK7 | CYP1A2 1397/4885CYP2A6 1550/4885TAAR1 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.